S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.58 HKD 3.77%
Market Cap: 10.6B HKD
Have any thoughts about
SSY Group Ltd?
Write Note

SSY Group Ltd
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SSY Group Ltd
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Long-Term Investments
HK$420.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
115%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Long-Term Investments
HK$8.4B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
54%
U
United Laboratories International Holdings Ltd
HKEX:3933
Long-Term Investments
ÂĄ7.6m
CAGR 3-Years
N/A
CAGR 5-Years
-58%
CAGR 10-Years
-42%
Sino Biopharmaceutical Ltd
HKEX:1177
Long-Term Investments
ÂĄ27.7B
CAGR 3-Years
17%
CAGR 5-Years
78%
CAGR 10-Years
36%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Long-Term Investments
HK$8.6B
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Long-Term Investments
$80.5m
CAGR 3-Years
-12%
CAGR 5-Years
-11%
CAGR 10-Years
-3%
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
10.6B HKD
Industry
Pharmaceuticals

SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.

Intrinsic Value
5.42 HKD
Undervaluation 34%
Intrinsic Value
Price
S

See Also

What is SSY Group Ltd's Long-Term Investments?
Long-Term Investments
420.2m HKD

Based on the financial report for Jun 30, 2024, SSY Group Ltd's Long-Term Investments amounts to 420.2m HKD.

What is SSY Group Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
115%

Over the last year, the Long-Term Investments growth was 5%.

Back to Top